EUVIMEDEUVIMED entdecken
Multizentrische Studie

Sex and ethnic disparities in hepatitis B evaluation and treatment across the world

Sahith Kudaravalli, Daniel Q Huang, Ming-Lun Yeh, Lindsey Trinh, P C Tsai, Yao-Chun Hsu, Leslie Y Kam, Vy H Nguyen, Eiichi Ogawa, Dong Hyun Lee, Takanori Ito, Tsunamasa Watanabe und 44 weitere

Journal of Hepatology · 2024-07 · 81 (1) · 33-41

DOI: 10.1016/j.jhep.2024.02.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Hepatology, 2024-07. Verfasst von Sahith Kudaravalli und 55 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States; Trinity College of Arts and Sc…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Healthcare Disparities. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Sun Yat-sen University, National Medical Research Council, Ministry of Health -Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Oral antiviral therapy with nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are limited. We examined rates of evaluation and treatment in patients from the REAL-B consortium. METHODS: This was a cross-sectional study nested within our retrospective multinational clinical consortium (2000-2021). We determined the proportions of patients receiving adequate evaluation, meeting AASLD treatment criteria, and initiating treatment at any time during the study period. We also identified factors associated with receiving adequate evaluation and treatment using multivariable logistic regression analyses. RESULTS: We analyzed 12,566 adult treatment-naïve patients with CHB from 25 centers in 9 countries (mean age 47.1 years, 41.7% female, 96.1% Asian, 49.6% Western region, 8.7% cirrhosis). Overall, 73.3% (9,206 patients) received adequate evaluation. Among the adequately evaluated, 32.6% (3,001 patients) were treatment eligible by AASLD criteria, 83.3% (2,500 patients) of whom were initiated on NAs, with consistent findings in analyses using EASL criteria. On multivariable logistic regression adjusting for age, sex, cirrhosis, and ethnicity plus region, female sex was associated with adequate evaluation (adjusted odds ratio [aOR] 1.13, p = 0.004), but female treatment-eligible patients were about 50% less likely to initiate NAs (aOR 0.54, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B, ChronicHealthcare DisparitiesHumansFemaleMaleCross-Sectional StudiesMiddle AgedRetrospective StudiesAdultSex FactorsEthnicityGlobal Health

Stichwörter der Autor:innen

GuidelinesInequalityLiver CancerMulti-centerUndertreatment

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States; Trinity College of Arts and Sciences, Duke University, Durham, North Carolina, United States.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.
  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical Universi…
  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Cancer Hospital/I-Shou University, Kaohsiung, Taiwan.
  • Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.

Förderung

  • National Sun Yat-sen University
  • National Medical Research Council
  • Ministry of Health -Singapore
  • Ministry of Education

Zitieren

APA

Kudaravalli, S., Huang, D. Q., Yeh, M. L., Trinh, L., Tsai, P. C., Hsu, Y. C., Kam, L. Y., Nguyen, V. H., Ogawa, E., Lee, D. H., Ito, T., Watanabe, T., Enomoto, M., Preda, C. M., Ko, M. K. L., Wan-Hin Hui, R., Atsukawa, M., Suzuki, T., Marciano, S., …, & Nguyen, M. H. (2024). Sex and ethnic disparities in hepatitis B evaluation and treatment across the world. Journal of Hepatology, 81(1), 33-41. https://doi.org/10.1016/j.jhep.2024.02.033

Vancouver

Kudaravalli S, Huang DQ, Yeh ML, Trinh L, Tsai PC, Hsu YC, et al. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world. Journal of Hepatology. 2024;81(1):33-41. doi:10.1016/j.jhep.2024.02.033

BibTeX
@article{Kudaravalli2024,
  author = {Kudaravalli, Sahith and Huang, Daniel Q and Yeh, Ming-Lun and Trinh, Lindsey and Tsai, P C and Hsu, Yao-Chun and Kam, Leslie Y and Nguyen, Vy H and Ogawa, Eiichi and Lee, Dong Hyun and Ito, Takanori and Watanabe, Tsunamasa and Enomoto, Masaru and Preda, Carmen Monica and Ko, Michael K L and Wan-Hin Hui, Rex and Atsukawa, Masanori and Suzuki, Takanori and Marciano, Sebastian and Barreira, Ana and Do, Son and Uojima, Haruki and Takahashi, Hirokazu and Quek, Sabrina X Z and Toe Wai Khine, Htet Htet and Ishigami, Masatoshi and Itokawa, Norio and Go, Min Seok and Kozuka, Ritsuzo and Marin, Raluca Ioana and Sandra, Irina and Li, Jiayi and Zhang, Jian Q and Wong, Christopher and Yoshimaru, Yoko and Vo, Dang K H and Tseng, Cheng-Hao and Lee, Chul-Jin and Inoue, Kaori and Maeda, Mayumi and Hoang, Joseph K and Chau, Angela and Chuang, Wan-Long and Dai, Chia-Yen and Huang, Jee-Fu and Huang, Chung-Feng and Buti, Maria and Tanaka, Yasuhito and Gadano, Adrian Carlos and Yuen, Man-Fung and Cheung, Ramsey and Lim, Seng Gee and Trinh, Huy N and Toyoda, Hidenori and Yu, Ming-Lung and Nguyen, Mindie H},
  title = {Sex and ethnic disparities in hepatitis B evaluation and treatment across the world},
  journal = {Journal of Hepatology},
  year = {2024},
  volume = {81},
  number = {1},
  pages = {33--41},
  doi = {10.1016/j.jhep.2024.02.033}
}
Kostenlos starten →